Insmed Incorporated
As of Oct 22, 2026, Insmed is in Stage 4, the downtrend phase, now in its first week (since Oct 20, 2026). It closed at $95.06, 55.0% below its 52-week high and below its 200-day average, which is falling.
Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is INSM early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
INSM among Biotechnology322nd of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
| …322 | INSM | Stage 4 · wk 1 | 27 | −19.7% |
Insmed: quick answers
What stage is Insmed in?
As of Oct 22, 2026, Insmed (INSM) is in Stage 4, the downtrend phase. It entered Stage 4 on Oct 20, 2026 and is in its first week there. What the four stages mean
Is Insmed in an uptrend?
No. Insmed is in a Stage 4 downtrend. It trades 25.4% below its 200-day average, which is falling.
How far is Insmed from its 52-week high?
Insmed closed at $95.06 on Oct 22, 2026, 55.0% below its 52-week high of $211.41. Its 52-week low is $91.88.
How has Insmed performed over the past year?
As of Oct 22, 2026, Insmed is down 42.5% over the past year and down 46.3% so far in 2026.
Which sector and industry is Insmed in?
Insmed is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It also develops brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1(DPP1) that is in phase 3 clinical trial for the treatment of bronchiectasis; and in phase 2 clinical trial for the treatment of chronic rhinosinusitis without nasal polyps and hidradenitis suppurativa. In addition, the company is developing treprostinil palmitil inhalation powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil, which is in phase 3 clinical trial for the treatment of pulmonary hypertension associated with interstitial lung disease; and phase 2 clinical trial for the treatment of pulmonary arterial hypertension. Further, it develops INS1201, a microdystrophin adeno-associated virus gene replacement therapy which is in phase 1 clinical trial for the treatment of Duchenne muscular dystrophy, as well as it is also developing pre-clinical research programs for gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. In addition, it provides INS1148, monoclonal antibody targeting stem cell factor called SCF248 that is in phase-2 clinical trial for the treatment of interstitial lung disease, and asthma; and INS1202, an intrathecally delivered gene therapy which is in phase 1 of clinical trial for the treatment of amyotrophic lateral sclerosis. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.